Aqtual Strengthens Executive Leadership to Advance Active Chromatin cfDNA Diagnostics and Precision Medicine Platform Aqtual, Inc., a precision medicine company focused on developing next-generation diagnostics based on active chromatin cell-free DNA (cfDNA), has announced the appointment of Ferhan Qureshi as…
Corrixr Therapeutics Appoints Nancy Whiting as Board Chair to Support Advancement of CXR101 Toward Clinical Development Corrixr Therapeutics, a preclinical genetic medicine company developing innovative therapies for squamous cell cancers, has announced the appointment of Nancy Whiting, PharmD, as Chair…
Hologic Expands CE-IVDR Approval for Aptima HPV Assay to Support Self-Collected Cervical Cancer Screening Samples Hologic, Inc. has announced that its Aptima® HPV Assay has received an expanded CE-IVDR marking in the European Union and the United Kingdom, allowing the…
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer to Accelerate Growth of xPloration® Single B-Cell Screening Platform OmniAb, Inc., a biotechnology company recognized for its advanced antibody discovery technologies that support the development of next-generation therapeutics, has announced the appointment…
Universal Brain Receives FDA 510(k) Clearance for UB ERP System, Advancing Objective Brain Function Assessment in Mental Health Care Universal Brain, a neurotechnology company focused on developing objective tools to measure brain function for mental health applications, has announced that…
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer to Advance RNA Medicine Pipeline and Genetic Disease Research Stoke Therapeutics, Inc. has announced the appointment of Thomas McCauley, Ph.D., as its new Chief Scientific Officer (CSO), reinforcing the company’s commitment…
PADCEV® Combination Approved for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Pfizer Inc. and Astellas Pharma Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv) in combination with the PD-1 inhibitor Keytruda® (pembrolizumab)…
Universal Orthodontic Lab Appoints Dr. Ryo Hamanaka as Chief Clinical Officer to Advance Clinical Innovation and Next-Generation Orthodontic Solutions Universal Orthodontic Lab, a leading orthodontic laboratory headquartered in Norwalk, California, has announced the appointment of Dr. Ryo Hamanaka as Chief…
Studion Promotes Brian Harrington to General Manager of Life Sciences Business to Drive Growth of eClinical Services Studion, a technology services company specializing in the design, development, and delivery of digital experiences for the Learning and Life Sciences sectors, has…
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Bausch + Lomb Corporation a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating…
Immunocine Cancer Center Appoints Vita S. Salsman as Executive Director to Advance Personalized Cancer Immunotherapy Immunocine Cancer Center has announced the appointment of Vita S. Salsman as its new Executive Director, a leadership move that reflects the organization’s continued commitment…
Paradromics Strengthens Clinical Leadership with Appointment of Dr. William J. Marks Jr. as Chief Clinical Officer Paradromics Inc., a clinical-stage neurotechnology company developing high-bandwidth brain-computer interface (BCI) systems, has announced the appointment of renowned neurologist and clinical scientist William J.…